Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic

MT Newswires Live

Jul 12, 2025

Novartis (NVS) has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in Delaware published Friday.

MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.

The patent for the drug expires on November 8, 2026, the court document said.

Novartis said it was "disappointed" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.

MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.

Novartis shares were down 2% in recent trading.

Price: 121.29, Change: -2.44, Percent Change: -1.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550965666"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550965666\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550965666?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 02:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550965666","market":"sh","top_or_hot":-1,"title":"Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic","media":"MT Newswires Live","content":"<html><body><p> Novartis (NVS) has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in <a href=\"https://laohu8.com/S/VMM\">Delaware</a> published Friday.</p><p>MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.</p><p>The patent for the drug expires on November 8, 2026, the court document said.</p><p>Novartis said it was \"disappointed\" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.</p><p>MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.</p><p>Novartis shares were down 2% in recent trading.</p><p>Price: 121.29, Change: -2.44, Percent Change: -1.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Loses Patent Infringement Suit Against MSN Pharmaceuticals for Entresto Generic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-12 02:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novartis (NVS) has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in <a href=\"https://laohu8.com/S/VMM\">Delaware</a> published Friday.</p><p>MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.</p><p>The patent for the drug expires on November 8, 2026, the court document said.</p><p>Novartis said it was \"disappointed\" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.</p><p>MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.</p><p>Novartis shares were down 2% in recent trading.</p><p>Price: 121.29, Change: -2.44, Percent Change: -1.97</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2550965666","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550965666","pubTimestamp":1752258819,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novartis  has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in Delaware published Friday.MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.The patent for the drug expires on November 8, 2026, the court document said.Novartis said it was \"disappointed\" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.Novartis shares were down 2% in recent trading.Price: 121.29, Change: -2.44, Percent Change: -1.97","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4007":"制药","NVS":"诺华","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4532":"文艺复兴科技持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","MSN":"Emerson Radio Corp","BK4578":"CAR-T","BK4078":"消费电子产品"},"translate_title":"诺华在针对MSN Pharmaceuticals的Entresto仿制药专利侵权诉讼中败诉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"MSN":1},"content_text":"Novartis (NVS) has lost a lawsuit that accused MSN Pharmaceuticals of infringing on its patent for chronic heart failure treatment drug Entresto, according to a federal court decision in Delaware published Friday.MSN Pharmaceuticals will be allowed to manufacture and sell a generic version of Novartis' drug, according to a decision from US District Judge Richard Andrews.The patent for the drug expires on November 8, 2026, the court document said.Novartis said it was \"disappointed\" and plans to appeal the decision, the company said in an emailed statement to MT Newswires.MSN Pharmaceuticals did not immediately reply to a request for comment from MT Newswires.Novartis shares were down 2% in recent trading.Price: 121.29, Change: -2.44, Percent Change: -1.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}